Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029
The 152-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
- Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029
- Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Leading Drugs:
- Yervoy (ipilimumab)
- Opdivo (nivolumab)
- Keytruda (pembrolizumab)
- Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Class:
- CTLA-4 Inhibitors
- PD-1 Inhibitors
- Pipeline Drugs
- Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by regional and national market:
- U.S.
- EU: Germany, France, Italy, U.K., Spain
- Japan
- APAC
- Profiles of the selected leading companies:
- AstraZeneca, Plc
- Bristol-Myers Squibb Co.
- Celldex Therapeutics, Inc.
- Incyte Corporation
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Roche Holding AG
- The Checkpoint Inhibitors Anti-Cancer Treatment Market Pipeline Analysis
- A SWOT analysis of the global checkpoint inhibitors anti-cancer treatment market
- Key Questions Answered by this Report:
- What are the global revenue prospects for the period 2018 to 2029?
- What are the leading national market potentials from 2018 to 2029?
- How is the checkpoint inhibitor anti-cancer treatment drugs market evolving?
- What is driving and restraining the checkpoint inhibitor anti-cancer treatment drugs market?
- What are the market shares of each segment of the overall checkpoint inhibitor anti-cancer treatment drugs market?
- How will main checkpoint inhibitor anti-cancer treatment submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
- How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
- Which therapies can succeed and what revenues could they generate to 2029?
- What will be the main commercial drivers for the market from 2018 to 2029?
- How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
- How will that industry evolve between 2018 and 2029, especially in R&D?
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market. You find data, trends and predictions.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2018
- 1.2 Benefits of This Report
- 1.3 How This Report Delivers
- 1.4 Key Questions Answered by This Analytical Report
- 1.5 Who is This Report For?
- 1.6 Methods of the Study
- 1.7 Frequently Asked Questions (FAQ)
- 1.8 Associated Visiongain Reports
- 1.9 About Visiongain
- 2. Introduction to the Checkpoint Inhibitor Anti-Cancer Treatment Drugs World Market 2018
- 2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
- 2.2 Checkpoint Inhibitor Treatment Drugs in Oncology
- 2.3 Application Segment
- 2.3.1 Lung Cancer
- 2.3.2 Bladder Cancer
- 2.3.3 Melanoma
- 2.3.4 Hodgkin Lymphoma
- 3. Leading Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market Forecasts 2019-2029 and Leading Companies in the World Market
- 3.1 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs in the Market 2019
- 3.1.1 Yervoy (ipilimumab) – Bristol-Myers Squibb
- 3.1.1.1 Yervoy: Sales Analysis
- 3.1.2 Opdivo (nivolumab) – Bristol-Myers Squibb/Ono Pharmaceutical
- 3.1.2.1 Opdivo: Sales Analysis
- 3.1.3 Keytruda (pembrolizumab) – Merck & Co.
- 3.1.3.1 Keytruda: Sales Analysis
- 3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market in 2018
- 3.2.1 Bristol-Myers Squibb Leads the Market
- 4. Checkpoint Inhibitor Anti-Cancer Treatment Drugs: World Market 2019-2029
- 4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2018
- 4.2 The World Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market: Revenue Forecasts 2019-20
- 4.3 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs Submarkets Forecast 2019-2029
- 4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2019-2029
- 4.3.2 The PD-1 Inhibitors Submarket Forecast 2019-2029
- 4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
- 4.3.4 Market Dynamics of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
- 4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
- 4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
- 4.3.4.3 Opportunity of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
- 4.3.4.4 Trends of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
- 5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
- 5.1 Epidemiology of Major Cancer types
- 5.1.1 Lung Cancer
- 5.1.2 Bladder Cancer
- 5.1.3 Melanoma
- 5.1.4 Hodgkin Lymphoma
- 5.1.5 Pancreatic Cancer
- 5.2 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
- 5.3 World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Regional Forecast, 2019-2029
- 5.3.1 How Will Regional Market Shares Change by 2029?
- 5.4 The US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
- 5.5 The EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
- 5.5.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
- 5.5.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
- 5.5.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
- 5.5.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
- 5.5.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
- 5.6 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
- 5.7 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
- 6. The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Pipeline Analysis 2019-2029
- 6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
- 6.1.1 Tecentriq (Atezolizumab)
- 6.1.2 Pidilizumab (CT-011) – CureTech, Ltd.
- 6.1.3 AMP-224 – GSK/Amplimmune
- 6.1.4 REGN2810 – Regeneron/Sanofi
- 6.1.5 Libtayo
- 6.2 CTLA-4 Inhibitors
- 6.2.1 Tremelimumab (CP-675,206) - AstraZeneca
- 6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
- 6.3.1 IMP321- Prima Biomed
- 6.3.2 BMS-986016 - Bristol-Myers Squibb
- 6.3.3 IMP701 – Prima BioMed/Novartis
- 6.4 KIR Inhibitors
- 6.4.1 Lirilumab (IPH2102/BMS-986015) – Innate Pharma/Bristol-Myers Squibb
- 6.5 Anti-NKG2A Inhibitors
- 6.5.1 IPH2201 – Innate Pharma/AstraZeneca/MedImmune
- 6.6 Other Checkpoint Inhibitors
- 6.6.1 VISTA Inhibitors
- 6.6.1.1 CA-170 – Curis Inc/Aurigene Discovery Technologies
- 6.6.1.2 NLG919 – NewLink Genetics
- 6.6.1.3 INCB024360 – Incyte/Roche
- 6.6.2 A2aR Inhibitors
- 6.6.2.1 HTL-1071 – AstraZeneca/Heptares
- 6.7 Clinical trial landscape for Immune checkpoint inhibitors
- 6.8 Clinical trial landscape for pd1/L1 Immune checkpoint inhibitors
- 7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
- 7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
- 7.1.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
- 7.1.1.1 A Novel Treatment Method that Harnesses the Immune System’s Vast Potential
- 7.1.1.2 Pricing of the Treatments Will Attract Companies
- 7.1.1.3 Cost of Treatment Will Restrain Market Access
- 7.1.1.4 Side Effects May Prohibit Growth
- 7.1.2 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
- 7.1.2.1 Biomarkers Pave the Way for Optimum Utility
- 7.1.2.2 Combination Therapies are Achieving Superior Results
- 7.1.2.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
- 7.1.2.4 Crowding of the Market with Similar Products
- 8. Company Profiles
- 8.1 AstraZeneca Plc.
- 8.1.1 Company Overview
- 8.1.2 Key Developments
- 8.2 Bristol-Myers Squibb Co.
- 8.2.1 Company Overview
- 8.2.2 Key Developments
- 8.3 Celldex Therapeutics Inc.
- 8.3.1 Company Overview
- 8.3.2 Key Developments
- 8.4 Incyte Corporation
- 8.4.1 Company Overview
- 8.4.2 Key Developments
- 8.5 Merck & Co., Inc.
- 8.5.1 Company Overview
- 8.5.2 Key Developments
- 8.6 Novartis Ag
- 8.6.1 Company Overview
- 8.6.2 Key Developments
- 8.7 Pfizer Inc.
- 8.7.1 Company Overview
- 8.7.2 Key Developments
- 8.8 Roche Holding Ag
- 8.8.1 Company Overview
- 8.8.2 Key Developments
- 9. Conclusions
- 9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Current World Outlook
- 9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market to 2029
- 9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2019-2029: The US and EU Will Retain Their Lead
- 9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
- Appendices
- Associated Visiongain Reports
- Visiongain Report Sales Order Form
- About Visiongain
- Visiongain report evaluation form
- List of Tables
- Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2018
- Table 3.1 Yervoy (Ipilimumab): Historical Sales ($bn, AGR%), 2015-2018
- Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2024
- Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2025-2029
- Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%),2024-2029
- Table 3.8 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Revenue ($bn), Market Share (%), 2018
- Table 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
- Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2018
- Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2018
- Table 4.4 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2018-2024
- Table 4.5 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2024-2029
- Table 4.6 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
- Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
- Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
- Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
- Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
- Table 4.11 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2018-2024
- Table 4.12 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2024-2029
- Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Market Shares (%), 2018
- Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2018-2024
- Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2024-2029
- Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2018-2024
- Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2024-2029
- Table 5.6 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 5.7 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 5.8 EU Market Shares (%), 2018-2024
- Table 5.9 EU Market Shares (%), 2024-2029
- Table 5.10 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 5.11 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 5.12 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 5.13 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 5.14 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 5.15 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 5.16 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 5.17 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 5.18 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 5.19 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 5.24 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
- Table 5.25 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
- Table 6.1 Selected Combination Therapies for Atezolizumab, 2018
- Table 6.2 Tecentriq Forecast: Revenue ($bn), 2018-2024
- Table 6.3 Tecentriq Forecast: Revenue ($bn), 2024-2029
- Table 6.4 Libtayo Forecast: Revenue ($bn), 2018-2024
- Table 6.5 Tremelimumab Forecast: Revenue ($bn), 2018-2024
- Table 6.6 Tremelimumab Forecast: Revenue ($bn), 2024-2029
- Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
- Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
- Table 8.1 AstraZeneca PLC. Profile 2018
- Table 8.2: AstraZeneca: Key Developments
- Table 8.3 Bristol-Myers Squibb Co. Profile 2018
- Table 8.4: Bristol-Myers Squibb: Key Developments
- Table 8.5 Celldex Therapeutics Inc. Profile 2018
- Table 8.6: Celldex Therapeutics: Key Developments
- Table 8.7 Incyte Corporation Profile 2018 (
- Table 8.8: Incyte: Key Developments
- Table 8.9 Merck & Co., Inc. Profile 2018
- Table 8.10: Merck & Co.: Key Developments
- Table 8.11 Novartis AG Profile 2018
- Table 8.12: Novartis: Key Developments
- Table 8.13 Pfizer Inc. Profile 2018 (
- Table 8.14: Pfizer: Key Developments
- Table 8.15: Roche Holding AG Profile 2018 (
- Table 8.16: Roche: Key Developments
- Table 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029
- Table 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn) Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029
- List of Figures
- Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Segmentation Overview, 2019
- Figure 3.1 Yervoy (ipilimumab): Historical Sales ($bn), 2015-2018
- Figure 3.2 Yervoy Forecast, Revenue ($bn), 2018-2029
- Figure 3.3 Opdivo Forecast, Revenue ($bn), 2018-2029
- Figure 3.4 Keytruda Forecast, Revenue ($bn), 2018-2029
- Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Revenue: Market Shares, 2018 (%)
- Figure 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
- Figure 4.2 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), 2018-2029
- Figure 4.3 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
- Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2018-2029
- Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2018-2029
- Figure 4.6 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares by Class (%), 2024
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook